Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
30 Results for "
AKR1B
" in MedChemExpress (MCE) Product Catalog:
Products (30)
30 Results for "AKR1B" in MCE Product Catalog:
3
Target:
Research Areas:
Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.
1
1 Cited Publications
Synonyms: Glucogallin; 1-O-Galloyl-β-D-glucose
1
Target:
Research Areas:
Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol [1] .
1
1 Cited Publications
Cat. No.: HY-N0310
CAS No.: 51330-27-9
1
Target:
Research Areas:
Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC50s of 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively, and a Ki of 0.38 nM for recombinant human AR. Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas [1] .
Target:
Research Areas:
AKR1B10-IN-1 is a potent inhibitor of AKR1B10 (Aldo-Keto Reductase 1B10) with an IC50 of 3.5 nM. AKR1B10-IN-1 suppresses proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells [1].
Cat. No.: HY-N0412
CAS No.: 117479-87-5
Category:
Iridoids Labiatae Terpenoids Phaseolus lunatus L. Plants Disease Research Fields Inflammation/Immunology
Target:
Cat. No.: HY-RS17235
Target:
Research Areas:
Akr1b1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Akr1b1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00532
Target:
Research Areas:
AKR1B1 Human Pre-designed siRNA Set A contains three designed siRNAs for AKR1B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00533
Target:
Research Areas:
AKR1B10 Human Pre-designed siRNA Set A contains three designed siRNAs for AKR1B10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-175331
CAS No.: 59935-47-6
Target:
Research Areas:
ALR2-IN-7 (Compound 5a) is a highly potent and selective aldose reductase (ALR2/AKR1B1) inhibitor (Ki=8.71 nM). ALR2-IN-7 is promising for research of diabetic complications (e.g., retinopathy, nephropathy) and cancers [1].
Cat. No.: HY-177415
CAS No.: 2353515-08-7
Target:
Research Areas:
JSD26 is a selective and orally active SCoR2 (AKR1A1) inhibitor with an IC50 of 93 nM. JSD26 has 10-fold selectivity for SCoR2 versus AKR1B1. JSD26 can be used for the study acute kidney injury (AKI) [1].
Cat. No.: HY-149254
Target:
Research Areas:
PTP1B/AKR1B1-IN-1 is a dual inhibitor of protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), with IC50s of 0.06 μM and 4.3 μM, respectively. PTP1B/AKR1B1-IN-1 also inhibits TC-PTP with an IC50 value of 9 μM. PTP1B/AKR1B1-IN-1 serves as an insulin-mimetic agent in murine myoblasts, and reduces AKR1B1-dependent sorbitol accumulation. PTP1B/AKR1B1-IN-1 inhibits development of type 2 diabetes mellitus (T2DM) to control blood glucose levels [1].
Cat. No.: HY-176719
CAS No.: 2632263-80-8
Research Areas:
AKR1B1/STAT3/SLC7A11-regulator-1 (5a) is an AKR1B1/STAT3/SLC7A11 regulator that reverses DOX resistance in MCF-7/ADR cells by enhancing ferroptosis activity. AKR1B1/STAT3/SLC7A11-regulator-1 can be used in breast cancer research [1].
Cat. No.: HY-149255
Target:
Research Areas:
PTP1B/AKR1B1-IN-2 (Compound 7f) is a dual PTP1B/AKR1B1 inhibitor (IC50s: 3.2 and 2.1 μM, Kis: 4.0 and 0.9μM). PTP1B/AKR1B1-IN-2 is an insulin-mimetic agent. PTP1B/AKR1B1-IN-2 improves glucose uptake in murine C2C12 myoblasts. PTP1B/AKR1B1-IN-2 can be used for research of Type 2 diabetes mellitus (T2DM) [1].
Cat. No.: HY-N0310R
CAS No.: 51330-27-9
Cat. No.: HY-122177
CAS No.: 314297-32-0
Target:
Research Areas:
MK181 is an aldose reductase (AR) inhibitor with IC50s of 0.71 μM and 4.5 μM for aldose reductase and AKR1B10, respectively. MK181 can bind into the external loop A subpocket of AKR1B10 [1].
Cat. No.: HY-175639
Target:
Research Areas:
ALR2-IN-8 is a potent aldose reductase (ALR2/AKR1B1) inhibitor with a KI of 7.34 nM. ALR2-IN-8 has extremely low toxicity to normal cells and has a weak direct killing effect on cancer cells. ALR2-IN-8 can used for the studies of diabetic and inflammation-linked disorders [1].
Cat. No.: HY-RS17238
Target:
Research Areas:
Akr1b10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Akr1b10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23688
Target:
Research Areas:
Akr1b1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Akr1b1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
